工程化表达靶向甲状腺髓样癌高表达抗原降钙素、CEA及RET M918T的免疫受体T细胞
甲状腺髓样癌(MTC)转移后仍不可治愈,多数表达降钙素和癌胚抗原(CEA),约40%携带RET M918T驱动突变。研究构建了靶向CEA的CAR、靶向降钙素/HLA-A*24:02的TCR及靶向RET M918T/HLA-DPB1*04:01/02的TCR,体外可产生效应细胞因子并杀伤抗原阳性细胞系,在免疫缺陷小鼠中过继转移抗CEA CAR或降钙素反应性TCR可实现肿瘤完全消退,RET M918T特异性TCR对突变肽及表达相应HLA和突变的MTC细胞有特异性反应。
要点
- 靶向CEA的CAR与靶向降钙素的TCR在体外可杀伤表达对应抗原的细胞系。
- 免疫缺陷小鼠中过继转移抗CEA CAR或降钙素反应性TCR可实现肿瘤完全消退。
- 靶向RET M918T/HLA-DPB1*04:01/02的TCR对突变肽及相应MTC细胞有特异性反应。
核心结论
- 临床前数据表明,使用靶向CEA、降钙素和/或RET M918T的基因工程T细胞治疗转移性MTC具有潜力。
研究设计与样本
- 临床前研究:构建并表征三种免疫受体——识别细胞外CEA的合成CAR、识别HLA-A*24:02呈递降钙素表位的TCR(分离自转基因小鼠)、识别HLA-DPB1*04:01/02限制性RET M918T新表位的TCR(分离自MTC患者),将其基因工程导入外周血T细胞,检测抗原特异性和抗肿瘤活性。
主要发现
- 表达抗CEA CAR或降钙素反应性TCR的T细胞在体外产生效应细胞因子,并对表达相应抗原的细胞系显示细胞毒性。
- 在携带人MTC细胞系的免疫缺陷小鼠中,过继转移表达抗CEA CAR或降钙素反应性TCR的T细胞导致肿瘤完全消退。
- 表达靶向RET M918T的HLA-DPB1*04:01/02限制性TCR(克隆自MTC患者外周血CD4+ T细胞)的T细胞,对负载突变肽的细胞及表达HLA-DPB1*04:01和RET M918T的MTC肿瘤细胞显示特异性反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Medullary thyroid cancer (MTC) is a rare malignancy originating from the calcitonin-producing C cells of the thyroid. Despite recent therapeutic advances, metastatic MTC remains incurable. Adoptive cell therapy (ACT) using genetically engineered T cells targeting either tissue-restricted tumor-associated antigens or mutated neoantigens has led to durable remissions in other metastatic solid tumors. The majority of MTC express the tumor-associated antigens calcitonin and carcinoembryonic antigen (CEA), and ∼40% of MTC harbor the RET M918T oncogenic driver mutation. Methods: We developed and characterized three immunoreceptors that recognize extracellular CEA, a calcitonin epitope presented by HLA-A*24:02, or an RET M918T neoepitope restricted by HLA-DPB1*04:01/02. The chimeric antigen receptor (CAR) targeting CEA was synthetically designed, while the T cell receptors (TCRs) targeting calcitonin and RET M918T were isolated from a transgenic mouse and patient with MTC, respectively. These immunoreceptors were genetically engineered into peripheral blood T cells and tested for antigen specificity and antitumor activity. Results: T cells expressing the anti-CEA CAR or the calcitonin-reactive TCR produced effector cytokines and displayed cytotoxicity against cell lines expressing their cognate antigen in vitro. In immunodeficient mice harboring a human MTC cell line, the adoptive transfer of T cells engineered to express the anti-CEA CAR or calcitonin-reactive TCR led to complete tumor regression. T cells expressing the HLA-DPB1*04:01/02-restricted TCR targeting RET M918T, which was cloned from peripheral blood CD4+ T cells of a patient with MTC, demonstrated specific reactivity against cells pulsed with the mutated peptide and MTC tumor cells that expressed HLA-DPB1*04:01 and RET M918T. Conclusion: The preclinical data presented herein demonstrate the potential of using genetically engineered T cells targeting CEA, calcitonin, and/or RET M918T to treat metastatic MTC.
引用
- Erickson TA, Shih YP, Fass J, et al. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T. Thyroid. 2022. PMID: 35587601. doi:10.1089/thy.2022.0020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。